Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

被引:0
|
作者
Wan, Zheng [1 ]
Shi, Man [1 ]
Gong, Yanqing [2 ]
Lucci, Massimo [3 ]
Li, Jinjin [4 ]
Zhou, Jiahai [5 ]
Yang, Xiao-Liang [6 ,7 ]
Lelli, Moreno [3 ,8 ]
He, Xiao [1 ,9 ]
Mao, Jiafei [10 ,11 ]
机构
[1] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug Dev, Shanghai Frontiers Sci Ctr Mol Intelligent Synth, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China
[2] China State Inst Pharmaceut Ind, Shanghai Inst Pharmaceut Ind, State Key Lab New Drug & Pharmaceut Proc, 285 Gebaini Rd, Shanghai 201203, Peoples R China
[3] CIRMMP Consorzio Interuniv Risonanze Magnet Met Pr, Via L Sacconi 6, I-50019 Florence, Italy
[4] Shanghai Jiao Tong Univ, Dept Micro Nanoelect, Key Lab Thin Film & Microfabricat, Minist Educ, Shanghai 200240, Peoples R China
[5] Chinese Acad Sci, Shenzhen Inst Synthet Biol, Shenzhen Inst Adv Technol, CAS Key Lab Quantitat Engn Biol, Shenzhen 518055, Peoples R China
[6] Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Coordinat Chem, Nanjing 210023, Peoples R China
[7] Nanjing Univ, Sch Chem & Chem Engn, Jiangsu Key Lab Adv Organ Mat, Nanjing 210023, Peoples R China
[8] Univ Florence, Magnet Resonance Ctr CERM, Dept Chem Ugo Schiff, Via Lastruccia 3, I-50019 Florence, Italy
[9] New York Univ Shanghai, Ctr Computat Chem, East China Normal Univ, Shanghai 200062, Peoples R China
[10] Chinese Acad Sci, Inst Chem, Beijing Natl Lab Mol Sci BNLMS, Zhongguancun North First St 2, Beijing 100190, Peoples R China
[11] Chinese Acad Sci, Inst Chem, Ctr Physicochem Anal & Measurement, Zhongguancun North First St 2, Beijing 100190, Peoples R China
来源
MOLECULES | 2024年 / 29卷 / 02期
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
HIV pre-exposure prophylaxis; cabotegravir; X-ray diffraction; NMR; DFT; AF-QM/MM; SOLID-STATE NMR; MODEL;
D O I
10.3390/molecules29020376
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cabotegravir is an integrase strand transfer inhibitor (INSTI) for HIV treatment and prevention. Cabotegravir-based long-acting pre-exposure prophylaxis (PrEP) presents an emerging paradigm for infectious disease control. In this scheme, a combination of a high efficacy and low solubility of anti-infection drugs permits the establishment of a pharmaceutical firewall in HIV-vulnerable groups over a long period. Although the structure-activity-relationship (SAR) of cabotegravir as an INSTI is known, the structural determinants of its low solubility have not been identified. In this work, we have integrated multiple experimental and computational methods, namely X-ray diffraction, solid-state NMR (SSNMR) spectroscopy, solution NMR spectroscopy, automated fragmentation (AF)-QM/MM and density functional theory (DFT) calculations, to address this question. The molecular organization of cabotegravir in crystal lattice has been determined. The combination of very-fast magic-angle-sample-spinning (VF MAS) SSNMR and solution NMR, as supported by AF-QM/MM and DFT calculations, permits the identification of structural factors that contribute to the low aqueous solubility of cabotegravir. Our study reveals the multitasking nature of pharmacophores in cabotegravir, which controls the drug solubility and, meanwhile, the biological activity. By unraveling these function-defining molecular features, our work could inspire further development of long-acting HIV PrEP drugs.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
    Prather, Caitlin
    Jeon, Chaeok
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (21) : 1898 - 1905
  • [2] Cabotegravir-Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
    Pepperrell, Toby
    Cross, Samuel
    Hill, Andrew
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):
  • [3] Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
    Anita J. Brogan
    Ashley E. Davis
    Claire E. Mellott
    Jeremy Fraysse
    Aimee A. Metzner
    Alan K. Oglesby
    [J]. PharmacoEconomics, 2024, 42 : 447 - 461
  • [4] Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
    Brogan, Anita J.
    Davis, Ashley E.
    Mellott, Claire E.
    Fraysse, Jeremy
    Metzner, Aimee A.
    Oglesby, Alan K.
    [J]. PHARMACOECONOMICS, 2024, 42 (04) : 447 - 461
  • [5] Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?
    Sahloff, Eric G.
    Hamons, Nikki
    Baumgartner, Kevin
    Duggan, Joan M.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07):
  • [6] Interrogating the promise of long-acting HIV pre-exposure prophylaxis
    Pike, Carey
    Bekker, Linda-Gail
    [J]. TRENDS IN MOLECULAR MEDICINE, 2023, 29 (02) : 93 - 98
  • [7] Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulation
    Han, K.
    Baker, M.
    Margolis, D.
    Spreen, W.
    Ford, S. L.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24
  • [8] INDIRECT TREATMENT COMPARISON (ITC) OF CABOTEGRAVIR LONG ACTING (CAB-LA) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) VERSUS NO PREP FOR HIV PREVENTION
    Hawkins, N.
    O'Brien, P.
    Thompson, J. C.
    Anderson, S. J.
    Manalastas, E.
    Dupont, Benjamin L.
    Schroeder, M.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S46 - S46
  • [9] Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
    Agrahari, Vivek
    Anderson, Sharon M.
    Peet, M. Melissa
    Wong, Andrew P.
    Singh, Onkar N.
    Doncel, Gustavo F.
    Clark, Meredith R.
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2022, 19 (10) : 1365 - 1380
  • [10] Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
    Engelman, Kathleen D.
    Engelman, Alan N.
    [J]. BIOCHEMISTRY, 2021, 60 (22) : 1731 - 1740